Strongyloidiasis: Difference between revisions

Jump to navigation Jump to search
Line 22: Line 22:


==[[Strongyloidiasis differential diagnosis|Differentiating Strongyloidiasis from other Diseases]]==
==[[Strongyloidiasis differential diagnosis|Differentiating Strongyloidiasis from other Diseases]]==
{| class="wikitable"
! colspan="7" |Differentiating Strongyloides stercoralis infection from other Nematode infections<ref name="Principles and Practice">Durand, Marlene (2015). "Chapter 288:Intestinal Nematodes (Roundworms)". Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases Updated Edition, Eighth Edition. Elsevier. pp. 3199–3207. ISBN 978-1-4557-4801-3.</ref><ref name="Murray and Nadel's Textbook of Respiratory Medicine">{{cite book |last1=Kim |first1=Kami |last2=Weiss |first2=Louis |last3=Tanowitz |first3=Herbert |title=Murray and Nadel's Textbook of Respiratory Medicine Sixth Edition |publisher=Elsevier |date=2016 |pages=682-698 |chapter=Chapter 39:Parasitic Infections |isbn=978-1-4557-3383-5}}</ref>
|-
|Nematode
|Transmission
|Direct Person-Person Transmission
|Duration of Infection
|Pulmonary Manifestation
|Location of Adult worm(s)
|Treatment
|-
|[[Ascaris lumbricoides]]
|Ingestion of infective ova
|No
|1-2 years
|
* [[Löffler's syndrome]] (usually about 9-12 days after exposure to ova)
* [[Cough]]
* Substernal discomfort
* [[Crackles]]
* [[Wheezing]]
* Transient opacities
|Free in the lumen of the small bowel
(primarily jejunum)
|
* [[Albendazole]]
* [[Mebendazole]]
* [[Pyrantel pamoate]]
* [[Ivermectin]]
* [[Levamisole]]
* [[Piperazine]]
|-
|[[Trichuris trichiura]]
(whipworm)
|Ingestion of infective [[ova]]
|No
|1-3 years
|No pulmonary migration, therefore, no pulmonary manifestation
|Anchored in the superficial mucosa of cecum and colon
|
* [[Albendazole]]
* [[Mebendazole]]
|-
|[[Hookworm]] ([[Necator americanus]] and [[Ancylostoma duodenale]])
|Skin penetration by filariform larvae
|No
|
* 3-5 years (Necator)
* 1 year (Ancylostoma)
|
* [[Löffler's syndrome]]
* Transient opacities
|Attached to the mucosa of mid-upper portion of the [[small bowel]]
|
* [[Albendazole]]
* [[Mebendazole]]
* [[Levamisole]]
* [[Pyrantel pamoate]]
|-
|[[Strongyloides stercoralis]]
|Filariform larvae penetrates skin or bowel mucosa
|Yes
|Lifetime of the host
|
* [[Löffler's syndrome]]
* Chronic [[cough]]
* [[Pneumonia]] or [[sepsis]] in hyperinfection
|Embedded in the mucosa of the [[duodenum]], [[jejunum]]
|
* [[Ivermectin]]
* [[Albendazole]]
* [[Thiabendazole]]
|-
|[[Enterobius vermicularis]] ([[pinworm]])
|Ingestion of infective [[ova]]
|Yes
|1 month
|Extraintestinal migration is very rare<ref name="pmid21879805">{{cite journal| author=Serpytis M, Seinin D| title=Fatal case of ectopic enterobiasis: Enterobius vermicularis in the kidneys. | journal=Scand J Urol Nephrol | year= 2012 | volume= 46 | issue= 1 | pages= 70-2 | pmid=21879805 | doi=10.3109/00365599.2011.609834 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21879805  }} </ref>
|Free in the lumen of [[cecum]], [[appendix]], adjacent [[colon]]
|
* [[Albendazole]]
* [[Mebendazole]]
* [[Pyrantel pamoate]]
* [[Ivermectin]]
* [[Levamisole]]
* [[Piperazine]]
|}


==[[Strongyloidiasis epidemiology and demographics|Epidemiology and Demographics]]==
==[[Strongyloidiasis epidemiology and demographics|Epidemiology and Demographics]]==

Revision as of 18:57, 4 May 2017

This page is about clinical aspects of the disease.  For microbiologic aspects of the causative organism(s), see Strongyloides stercoralis.
Strongyloidiasis
Classification and external resources
Micrograph showing strongyloidiasis; a fragment of a worm is seen in the lower right hand corner. H&E stain.

For patient information, click here

Strongyloidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Strongyloidiasis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Strongyloidiasis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Strongyloidiasis

CDC on Strongyloidiasis

Strongyloidiasis in the news

Blogs on Strongyloidiasis

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Strongyloides infection

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Template:WH Template:WS